OCT 28 2026
GSK — bepirovirsen $GSK
for chronic hepatitis B infection
Accepted APR 28 2026.
About
Chronic hepatitis B is a viral infection that attacks the liver and can become a persistent, long-term illness. Bepirovirsen is an antisense oligonucleotide designed to bind to and degrade the virus's specific genetic material (mRNA). By silencing this viral blueprint, the drug aims to reduce the amount of virus in the body, which could potentially lead to a functional cure for the infection.
Pivotal trial
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on bepirovirsen
- Bepirovirsen Induces Clinical Cure of Chronic HBV Among a Fifth of Patients - Gastroenterology Advisor
- Chronic hepatitis B: Bepirovirsen delivers functional cure in about 1 in 5 on NA therapy - Vera Health
- Bepirovirsen Achieves Functional Cure in HBV Phase 3 Trial - Medscape
- GSK’s bepirovirsen shows promising results in chronic hepatitis B trials By Investing.com - Investing.com Nigeria
- Chronic hepatitis B: Bepirovirsen plus NA achieves functional cure after fixed-duration therapy - Vera Health